Using MarketScan data, another study of MASLD cirrhosis with T2D (459 GLP‐1 RA users vs. 4837 non‐users) found lower risks of compensated cirrhosis (HR 0.64 [0.50–0.80]), hepatocellular carcinoma (HR 0.47 [0.22–0.98]), and liver transplantation (HR 0.51 [0.27–0.93]) [17]. This evidence concerns the gene GLP1R and hepatocellular carcinoma.